Featured by Newsweek & World Class Media Outlets

Interviews

Industry

Jacob Duer
Jacob Duer
CEO & President
Alliance to End Plastic Waste
2024-05-10

Our main objective is to support the private sector in aiding governments with policy implementation on waste management. This clear distinction helps us maintain the integrity of our efforts and ensures that we are about action, showcasing sustainable practices and solutions on the ground.

READ MORE
Anand Parikh
Anand Parikh
CEO & Founder
Faeth Therapeutics
2024-05-09

Our lead therapy program focuses on the PI3 kinase pathway, a key driver in cancer proliferation and metabolism. Traditional treatments have targeted a single component of this pathway, allowing tumors to find escape routes.

 

READ MORE
Dr. Stephen Rapundalo
Dr. Stephen Rapundalo
President & Chief Executive Officer
Michbio (Michigan Biosciences Industry Association)
2024-05-08

Our top priority in Michigan has been to re-establish an R&D tax credit for nearly 15 years. This is crucial for our competitiveness in the global life sciences marketplace, especially for early-stage companies.

READ MORE
Michael McMullen
Michael McMullen
President & CEO
Agilent Technologies
2024-05-08

Our approach encompasses three key areas: advancing scientific discoveries, ensuring the safety of pharmaceuticals, and reducing the cost of drug development.

READ MORE
Sarah Boyce
Sarah Boyce
President & CEO
Avidity Biosciences
2024-05-08

Our strategy revolves around making a substantial difference in the lives of people living with rare diseases, which, in turn, supports a solid business rationale for our focus.

READ MORE
Gina Chapman
Gina Chapman
President & CEO
CARGO Therapeutics
2024-05-08

Our focus at CARGO is to innovate within the autologous therapy framework, ensuring a scalable and efficient process that can meet patient needs while maintaining high manufacturing standards.

READ MORE
Dr. Pascal Touchon
Dr. Pascal Touchon
President & CEO
Atara Biotherapeutics
2024-05-08

We are planning a first study in lupus nephritis with this new investigational therapy, demonstrating our commitment to rebounding from setbacks and exploring innovative solutions in treating autoimmune diseases.

READ MORE
Ram Aiyar
Ram Aiyar
CEO
Korro Bio
2024-05-08

Korro Bio's approach is distinct in leveraging RNA modification to potentially address a wide range of diseases, emphasizing the importance of understanding the intricate relationship between DNA, RNA, and protein synthesis in human biology.

READ MORE
Ivana Magovčević-Liebisch
Ivana Magovčević-Liebisch
President & CEO
Vigil Neuroscience
2024-05-08

Our treatments are potentially disease-modifying, aiming to slow down or even arrest disease progression in conditions like ALSP and Alzheimer's.

READ MORE
Sean McClain
Sean McClain
CEO
Absci
2024-05-08

Our AI model can generate antibodies for all potential target locations, offering functionality that was previously unachievable. This approach has allowed us to drug previously un-druggable targets, creating new biology and first-in-class assets.

READ MORE